VUITYTM has a well-established safety and tolerability profile.1

In the studies, there was a low discontinuation rate (1.3%) due to adverse events (AEs)2

1.3% Discontinued VUITY™ due to AEs2

(5/375) vs 0.5% vehicle (2/374)

0.5% Discontinued VUITY™ due to headache2

(2/375) vs 0.3% vehicle (1/374)

No
serious AEs
were
observed2

Most AEs were reported as mild and transient.2

The majority of treatment-emergent adverse events (TEAEs) were deemed by the investigator to be mild in severity. TEAEs of moderate severity were reported for 4.0% of participants [15/375] in the VUITY™ group and 2.4% of participants [9/374] in the vehicle group. Severe TEAEs were reported for 1.1% [4/375] of participants in the VUITY™ group and 0.5% [2/374] of participants in the vehicle group.2

Rate of TEAEs in GEMINI 1 and GEMINI 2 (pooled data)1,2

Chart of treatment-emergent adverse events for VUITYTM

85% of VUITY™ participants in clinical trials didn’t experience headaches2

Most headaches were reported as mild and transient. Participants were asked if they experienced a headache and, if so, to rate its severity at every study visit.2

Get the latest news about VUITYTM

Not an actual patient